source
- Moderna and Merck report late-stage success for personalized mRNA cancer vaccineModerna and Merck announced that their personalized cancer vaccine achieved its primary goals in a late-stage clinical trial, sparking enthusiasm across the biotech community. The experimental the…
- Gilead secures another FDA approval for HIV therapy, bolstering lenacapavir portfolioGilead Sciences announced that the U.S. Food and Drug Administration has approved a new HIV treatment, adding to the company's growing portfolio of antiviral drugs. The approval extends the reach o…